Bracco Diagnostics Inc. Receives U.S. FDA Approval for Expanded Labeling of MultiHance® (gadobenate dimeglumine) Injection in Magnetic Resonance Angiography
7/27/2012 10:02:47 AM
PRINCETON, N.J.--(BUSINESS WIRE)--Bracco Diagnostics Inc., the US-based company of the Bracco Group – one of the world’s leading companies in the diagnostic imaging business – today announced that the U.S. Food and Drug Administration (FDA) has approved the use of MultiHance® (gadobenate dimeglumine) Injection, 529 mg/mL, in magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease. MultiHance was already the highest relaxivity gadolinium-based contrast agent (GBCA) available for intravenous use in magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and pediatric patients. The recommended dose for both MRI of the CNS and MRA examinations is 0.1 mmol/kg (0.2 mL/kg) of MultiHance.
comments powered by